341 related articles for article (PubMed ID: 25120354)
1. Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review.
Besada E
Patient Prefer Adherence; 2014; 8():1051-9. PubMed ID: 25120354
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA).
Burmester GR; Rubbert-Roth A; Cantagrel A; Hall S; Leszczynski P; Feldman D; Rangaraj MJ; Roane G; Ludivico C; Bao M; Rowell L; Davies C; Mysler EF
Ann Rheum Dis; 2016 Jan; 75(1):68-74. PubMed ID: 26056119
[TBL] [Abstract][Full Text] [Related]
3. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
McLaughlin M; Östör A
Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607
[TBL] [Abstract][Full Text] [Related]
4. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis.
Ogata A; Tanimura K; Sugimoto T; Inoue H; Urata Y; Matsubara T; Kondo M; Ueki Y; Iwahashi M; Tohma S; Ohta S; Saeki Y; Tanaka T;
Arthritis Care Res (Hoboken); 2014 Mar; 66(3):344-54. PubMed ID: 23983039
[TBL] [Abstract][Full Text] [Related]
5. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis.
Burmester GR; Choy E; Kivitz A; Ogata A; Bao M; Nomura A; Lacey S; Pei J; Reiss W; Pethoe-Schramm A; Mallalieu NL; Wallace T; Michalska M; Birnboeck H; Stubenrauch K; Genovese MC
Ann Rheum Dis; 2017 Jun; 76(6):1078-1085. PubMed ID: 28007755
[TBL] [Abstract][Full Text] [Related]
6. Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis -- focus on subcutaneous tocilizumab.
Nakashima Y; Kondo M; Miyahara H; Iwamoto Y
Drug Des Devel Ther; 2014; 8():913-9. PubMed ID: 25045250
[TBL] [Abstract][Full Text] [Related]
7. Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs oranti-tumor necrosis factor.
Abdulkader OAF; Qushmaq K; Aljishi F
Ann Saudi Med; 2016; 36(3):190-6. PubMed ID: 27236390
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.
Lauper K; Nordström DC; Pavelka K; Hernández MV; Kvien TK; Kristianslund EK; Santos MJ; Rotar Ž; Iannone F; Codreanu C; Lukina G; Gale SL; Sarsour K; Luder Y; Courvoisier DS; Gabay C
Ann Rheum Dis; 2018 Sep; 77(9):1276-1282. PubMed ID: 29730637
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of tocilizumab as monotherapy or in combination with methotrexate in Tunisian patients with active rheumatoid arthritis and inadequate response to disease-modifying anti-rheumatic drugs in conditions close to clinical practice.
Bouajina E; Zakraoui L; Kchir M; Kochbati S; Baklouti S
Clin Rheumatol; 2020 May; 39(5):1449-1455. PubMed ID: 31838637
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous tocilizumab for the treatment of rheumatoid arthritis.
Mitchell E; Jones G
Expert Rev Clin Immunol; 2016; 12(2):103-14. PubMed ID: 26629984
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous tocilizumab: recent advances for the treatment of rheumatoid arthritis.
Ogata A; Kato Y; Higa S; Maeda K
Expert Opin Drug Deliv; 2019 Jun; 16(6):639-648. PubMed ID: 31088167
[TBL] [Abstract][Full Text] [Related]
12. Tocilizumab in the treatment of rheumatoid arthritis and beyond.
Shetty A; Hanson R; Korsten P; Shawagfeh M; Arami S; Volkov S; Vila O; Swedler W; Shunaigat AN; Smadi S; Sawaqed R; Perkins D; Shahrara S; Sweiss NJ
Drug Des Devel Ther; 2014; 8():349-64. PubMed ID: 24729685
[TBL] [Abstract][Full Text] [Related]
13. Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab.
Negoescu AF; Östör AJ
Rheumatol Ther; 2015 Jun; 2(1):17-31. PubMed ID: 27747493
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study.
Ogata A; Tanaka Y; Ishii T; Kaneko M; Miwa H; Ohsawa S; Yamakawa R;
Mod Rheumatol; 2019 Sep; 29(5):767-774. PubMed ID: 30299202
[No Abstract] [Full Text] [Related]
15. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs.
Strangfeld A; Richter A; Siegmund B; Herzer P; Rockwitz K; Demary W; Aringer M; Meißner Y; Zink A; Listing J
Ann Rheum Dis; 2017 Mar; 76(3):504-510. PubMed ID: 27405509
[TBL] [Abstract][Full Text] [Related]
16. Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study.
Ogata A; Amano K; Dobashi H; Inoo M; Ishii T; Kasama T; Kawai S; Kawakami A; Koike T; Miyahara H; Miyamoto T; Munakata Y; Murasawa A; Nishimoto N; Ogawa N; Ojima T; Sano H; Shi K; Shono E; Suematsu E; Takahashi H; Tanaka Y; Tsukamoto H; Nomura A;
J Rheumatol; 2015 May; 42(5):799-809. PubMed ID: 25834203
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous tocilizumab alone or with a csDMARD in rheumatoid arthritis patients: subanalysis of Italian data from a multicenter phase IIIb/IV trial.
Bazzichi L; Nacci F; Sinigaglia L; Bianchino L; Caporali R
Clin Rheumatol; 2019 Mar; 38(3):841-849. PubMed ID: 30421069
[TBL] [Abstract][Full Text] [Related]
18. Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review.
Al-Shakarchi I; Gullick NJ; Scott DL
Patient Prefer Adherence; 2013; 7():653-66. PubMed ID: 23869169
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.
Burmester GR; Rigby WF; van Vollenhoven RF; Kay J; Rubbert-Roth A; Blanco R; Kadva A; Dimonaco S
Ann Rheum Dis; 2017 Jul; 76(7):1279-1284. PubMed ID: 28389552
[TBL] [Abstract][Full Text] [Related]
20. Patterns of Prednisone Use in Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine US Clinical Practice.
Pappas DA; Etzel CJ; Zlotnick S; Best J; Blachley T; Kremer JM
Rheumatol Ther; 2019 Sep; 6(3):421-433. PubMed ID: 31240499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]